سامانه جستجوی جامع منابع دانشگاه علوم پزشکی جندی شاپور اهواز



عنوان اجزاء : Annual new drug approvals (NDAs) per billion USD pharmaceutical business expenditure on R&D in the United States, inflation-adjusted

ناشر : Organisation for Economic Co-Operation and Development (OECD)

DOI کد :

10.1787/health_glance-2017-graph186-en

سال انتشار : 2017

نوع : اجزاء

لینک خروجی به اجزاء

@incollection{1,
    doi = {10.1787/health_glance-2017-graph186-en},
    url = {http://dx.doi.org/10.1787/health_glance-2017-graph186-en},
    year = 2017,
    publisher = {Organisation for Economic Co-Operation and Development  (OECD)},
    pages = {},
    author = {},
    title = {Annual new drug approvals (NDAs) per billion USD pharmaceutical business expenditure on R&D in the United States, inflation-adjusted}
}
TY  - DATA
DO  - 10.1787/health_glance-2017-graph186-en
UR  - http://dx.doi.org/10.1787/health_glance-2017-graph186-en
TI  - Annual new drug approvals (NDAs) per billion USD pharmaceutical business expenditure on R&D in the United States, inflation-adjusted
PY  - 2017
PB  - Organisation for Economic Co-Operation and Development  (OECD)
SP  - 
AU  -
, T. (2017). Annual new drug approvals (NDAs) per billion USD pharmaceutical business expenditure on R&D in the United States, inflation-adjusted. doi:10.1787/health_glance-2017-graph186-en
“Annual new drug approvals (NDAs) per billion USD pharmaceutical business expenditure on R&D in the United States, inflation-adjusted.” (2017)